Methodological aspects of Tc-99m-sestamibi guided biopsy in breast cancer
| Autor: | L. M. Pereira Arias-Bouda, R.A. Valdés Olmos, Angela Collarino, A. F. van der Hoeven |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Breast imaging medicine.medical_treatment Review Article 99mTc-sestamibi 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Breast cancer Biopsy medicine Mammography Radiology Nuclear Medicine and imaging Radioguided-biopsy medicine.diagnostic_test business.industry Interventional radiology Breast-specific gamma-imaging 99mTc Sestamibi medicine.disease Molecular breast Imaging Occult Radiation therapy 030220 oncology & carcinogenesis Tc-99m-sestamibi Breast-specific γ-imaging Radiology business |
| Zdroj: | Clinical and Translational Imaging, 4(5), 367-376 Clinical and Translational Imaging |
| DOI: | 10.1007/s40336-016-0201-z |
| Popis: | Purpose This review aims to discuss the methodological aspects of dedicated molecular breast imaging (MBI) using 99mTc-sestamibi as radiotracer to guide biopsy of occult or unclear breast lesions on mammography (MG) and ultrasound (US) that are suspicious on MBI (BI-RADS criteria 4 and 5), including its advantages, limitations and future clinical applications. Methods Literature search was performed using the PubMed/MEDLINE database and “99mTc-sestamibi”, “biopsy” and “breast cancer” as keywords. The search was restricted to English language. Results There are few studies on 99mTc-sestamibi guided biopsy methods; to our knowledge, no full studies have yet been reported on clinical validation of this new biopsy procedure. This review describes technical aspects of 99mTc-sestamibi guided biopsy and discusses the advantages and limitations of this procedure in comparison with MG, US and MRI-guided biopsy. Conclusions MBI-guided biopsy appears to be a complementary modality and is principally indicated in the case of occult or unclear breast lesions on MG/US, that are suspicious on MBI. The future indication is in targeted biopsies in patients with large heterogeneous tumours. Further studies are needed to define the accuracy of this biopsy procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|